I-DXd

Phase 2Small molecule

Merck & Co.

I-DXd is one of 162 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

161

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Esophageal CancerActive, not recruiting

Lung NeoplasmRecruiting

Non-Small Cell Lung CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Oesophageal Squamous Cell CarcinomaRecruiting

Small Cell Lung Cancer Extensive StageRecruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

Lung NeoplasmPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Oesophageal Squamous Cell CarcinomaPreclinical

Recruiting

Small Cell Lung Cancer Extensive StagePreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

I-DXd

Merck & Co.

Phase 2

4 2

Imjudo

AstraZeneca

Preclinical

5 3

Vizimpro

Pfizer

Preclinical

4 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Remeron

OOrganon and Co

Preclinical

1 7

Treatment

GSK

Preclinical

1 8

Vidaza

Bristol-Myers Squibb

Preclinical

1 9

REGN2810

Regeneron

Preclinical

1 10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Oesophageal Squamous Cell Carcinoma

NCT07405151

Q4 2030

PreclinicalRecruiting

Small Cell Lung Cancer Extensive Stage

NCT07227597

Q1 2032

PreclinicalRecruiting

Esophageal Squamous Cell Carcinoma

NCT06780111

Phase 2Recruiting

Lung Neoplasm

NCT06780098

Clinical

Trials by Indication[1]

Small Cell Lung Cancer Extensive Stage1 trial

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07227597·170 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780098·144 enrolled

Oesophageal Squamous Cell Carcinoma1 trial

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07405151·60 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780111·298 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for I-DXd. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — I-DXd compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for I-DXd. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

I-DXd

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2030

Q1 2032

Trials by Indication[1]

Small Cell Lung Cancer Extensive Stage1 trial

Lung Neoplasm1 trial

Oesophageal Squamous Cell Carcinoma1 trial

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News